Inclusion Criteria:
- ≥ 55 years of age inclusive at the time of signing the informed consent
- Newly diagnosed, histologically confirmed de novo Acute Myeloid Leukemia (AML) or AML
secondary to prior myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia
(CMML)
- Should have undergone induction therapy with intensive chemotherapy with or without
consolidation therapy as recommended in appropriate guideline(s) or equivalent regimen
according to institutional standard: having achieved first complete remission
(CR)/complete remission with incomplete blood count recovery (CRi) status within 4
months prior to starting study therapy
Exclusion Criteria:
- Suspected or proven acute promyelocytic leukemia; or AML with previous hematologic
disorder such as chronic myeloid leukemia or myeloproliferative neoplasms, excluding
MDS and CMML
- Prior bone marrow or stem cell transplantation
- Received therapy with hypomethylating agents for MDS and went on to develop AML within
four months of discontinuing the therapy with hypomethylating agents
- Have achieved CR/CRi following therapy with hypomethylating agents
Other protocol-defined inclusion/exclusion criteria apply
Recruiting
